Interaction between DNA Polymerase lambda and anticancer nucleoside analogs

J Biol Chem. 2010 May 28;285(22):16874-9. doi: 10.1074/jbc.M109.094391. Epub 2010 Mar 26.

Abstract

The anticancer activity of cytarabine (AraC) and gemcitabine (dFdC) is thought to result from chain termination after incorporation into DNA. To investigate their incorporation into DNA at atomic level resolution, we present crystal structures of human DNA polymerase lambda (Pol lambda) bound to gapped DNA and containing either AraC or dFdC paired opposite template dG. These structures reveal that AraC and dFdC can bind within the nascent base pair binding pocket of Pol lambda. Although the conformation of the ribose of AraCTP is similar to that of normal dCTP, the conformation of dFdCTP is significantly different. Consistent with these structures, Pol lambda efficiently incorporates AraCTP but not dFdCTP. The data are consistent with the possibility that Pol lambda could modulate the cytotoxic effect of AraC.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cytarabine / pharmacology
  • DNA / chemistry
  • DNA Polymerase beta / metabolism*
  • DNA Repair
  • DNA Replication
  • DNA-Directed DNA Polymerase / chemistry
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / pharmacology
  • Dose-Response Relationship, Drug
  • Gemcitabine
  • Humans
  • Kinetics
  • Mice
  • Models, Molecular
  • Nucleosides / chemistry*
  • Nucleotides / chemistry

Substances

  • Antineoplastic Agents
  • Nucleosides
  • Nucleotides
  • Cytarabine
  • Deoxycytidine
  • DNA
  • DNA polymerase beta2
  • DNA Polymerase beta
  • DNA-Directed DNA Polymerase
  • Gemcitabine

Associated data

  • PDB/3MDA
  • PDB/3MDC